HC Wainwright Comments on Aeterna Zentaris Inc.’s FY2023 Earnings (NASDAQ:AEZS)

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) – HC Wainwright decreased their FY2023 earnings per share estimates for Aeterna Zentaris in a report released on Monday, November 13th. HC Wainwright analyst B. Pachaiyappan now expects that the biopharmaceutical company will post earnings of ($3.22) per share for the year, down from their prior estimate of ($2.67). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Aeterna Zentaris’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Aeterna Zentaris’ Q4 2023 earnings at ($0.97) EPS, Q1 2024 earnings at ($0.81) EPS, Q2 2024 earnings at ($0.82) EPS, Q3 2024 earnings at ($0.87) EPS, Q4 2024 earnings at ($0.87) EPS and FY2024 earnings at ($3.37) EPS.

Separately, StockNews.com assumed coverage on Aeterna Zentaris in a report on Tuesday. They issued a “sell” rating for the company.

Aeterna Zentaris Trading Down 3.3 %

Shares of NASDAQ:AEZS opened at $1.48 on Wednesday. The stock has a market capitalization of $7.19 million, a price-to-earnings ratio of -0.31 and a beta of 1.56. The stock has a fifty day simple moving average of $2.01 and a two-hundred day simple moving average of $2.55. Aeterna Zentaris has a 12-month low of $1.36 and a 12-month high of $4.00.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.